低剂量螺内酯是否能增强慢性肾病患者的心血管保护作用？ - Suppr

Suppr

超能文献

Does low-dose spironolactone increase cardiovascular protection in patients with chronic kidney disease?

作者信息

García-Carro Clara, Sarafidis Pantelis

机构信息

Nephrology Department, San Carlos Clinical University Hospital; Madrid Complutense University, Madrid, Spain.

1st Department of Nephrology, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece.

出版信息

Clin Kidney J. 2025 Feb 11;18(3):sfaf038. doi: 10.1093/ckj/sfaf038. eCollection 2025 Mar.

DOI:10.1093/ckj/sfaf038

PMID:40065846

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11892426/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa6e/11892426/092a510295ca/sfaf038fig1.jpg

相似文献

Does low-dose spironolactone increase cardiovascular protection in patients with chronic kidney disease?低剂量螺内酯是否能增强慢性肾病患者的心血管保护作用？

Clin Kidney J. 2025 Feb 11;18(3):sfaf038. doi: 10.1093/ckj/sfaf038. eCollection 2025 Mar.

Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT.醛固酮受体拮抗剂在慢性肾脏病中的益处：BARACK-D随机对照试验

Health Technol Assess. 2025 Mar;29(5):1-130. doi: 10.3310/PYFT6977.

Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial.螺内酯预防早期慢性肾脏病心血管事件（STOP-CKD）：一项随机对照试验的研究方案

Trials. 2014 May 6;15:158. doi: 10.1186/1745-6215-15-158.

Low-dose Spironolactone Combined with ACEIs/ARBs May Reduce Cardiovascular Events in Patients with CKD Stages 3b-5: A Nationwide Population-Based Cohort Study in Taiwan.低剂量螺内酯联合ACEIs/ARBs可能降低3b-5期慢性肾脏病患者的心血管事件：台湾一项基于全国人群的队列研究

Int J Med Sci. 2025 Feb 24;22(6):1404-1414. doi: 10.7150/ijms.103390. eCollection 2025.

Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial.低剂量螺内酯与中度慢性肾脏病的心血管结局：一项随机对照试验

Nat Med. 2024 Dec;30(12):3634-3645. doi: 10.1038/s41591-024-03263-5. Epub 2024 Sep 30.

Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney disease------Balance of efficacy and risk.射血分数保留的心力衰竭合并慢性肾脏病患者中螺内酯剂量与预后的关联——疗效与风险的平衡

Front Pharmacol. 2023 Jan 27;14:1084442. doi: 10.3389/fphar.2023.1084442. eCollection 2023.

Long-Term Effects of Spironolactone on Kidney Function and Hyperkalemia-Associated Hospitalization in Patients with Chronic Kidney Disease.螺内酯对慢性肾脏病患者肾功能及高钾血症相关住院的长期影响。

J Clin Med. 2018 Nov 21;7(11):459. doi: 10.3390/jcm7110459.

Spironolactone Improves the All-Cause Mortality and Re-Hospitalization Rates in Acute Myocardial Infarction with Chronic Kidney Disease Patients.螺内酯可改善合并慢性肾脏病的急性心肌梗死患者的全因死亡率和再住院率。

Front Pharmacol. 2021 May 31;12:632978. doi: 10.3389/fphar.2021.632978. eCollection 2021.

Heart failure and chronic kidney disease: should we use spironolactone?心力衰竭与慢性肾脏病：我们应该使用螺内酯吗？

Am J Med Sci. 2015 Aug;350(2):147-51. doi: 10.1097/MAJ.0000000000000514.

Results and lessons from the Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial.螺内酯预防早期慢性肾脏病心血管事件（STOP-CKD）随机对照试验的结果与经验教训。

BMJ Open. 2016 Feb 25;6(2):e010519. doi: 10.1136/bmjopen-2015-010519.

本文引用的文献

Nat Med. 2024 Dec;30(12):3634-3645. doi: 10.1038/s41591-024-03263-5. Epub 2024 Sep 30.

Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial.非糖尿病慢性肾脏病患者使用非奈利酮（除标准治疗外）延缓肾病进展的随机试验（FIND-CKD）的设计与基线特征

Nephrol Dial Transplant. 2025 Feb 4;40(2):308-319. doi: 10.1093/ndt/gfae132.

A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension.2023 年欧洲高血压学会（ESH）动脉高血压管理指南的肾脏病实践欧洲肾脏协会（ERA）概要

Nephrol Dial Transplant. 2024 May 31;39(6):929-943. doi: 10.1093/ndt/gfae041.

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.在 2 型糖尿病合并慢性肾脏病患者中，用非奈利酮治疗的心血管和肾脏结局：FIDELITY 汇总分析。

Eur Heart J. 2022 Feb 10;43(6):474-484. doi: 10.1093/eurheartj/ehab777.

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.在肾脏病和 2 型糖尿病患者中用非奈利酮发生的心血管事件。

N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28.

Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: A Milestone Achieved.钠-葡萄糖协同转运蛋白2抑制剂和盐皮质激素受体拮抗剂对慢性肾脏病的心血管保护作用：一项里程碑式的成果。

Hypertension. 2021 May 5;77(5):1442-1455. doi: 10.1161/HYPERTENSIONAHA.121.17005. Epub 2021 Mar 29.

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.非奈利酮对 2 型糖尿病患者慢性肾脏病结局的影响。

N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.

Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials.醛固酮受体拮抗剂在蛋白尿性肾脏疾病中的作用：一项随机对照试验的系统评价和荟萃分析。

J Hypertens. 2019 Dec;37(12):2307-2324. doi: 10.1097/HJH.0000000000002187.

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis.患有和不患有糖尿病者的肾脏疾病指标与死亡率和终末期肾病的相关性：一项荟萃分析。

Lancet. 2012 Nov 10;380(9854):1662-73. doi: 10.1016/S0140-6736(12)61350-6. Epub 2012 Sep 24.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验